Transgene today announced its financial reporting dates for 2018: March 21, 2017 Fiscal Year Results.
STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:
TRANSGENE S.A. (Paris:TNG) today announced its financial reporting dates for 2018:
| March 21: | 2017 Fiscal Year Results | ||||
| April 26: | First Quarter 2018 Financial Results | ||||
| May 23: | Annual Shareholders’ Meeting | ||||
| September 19: | First Half 2018 Financial Results | ||||
| October 25: | Third Quarter 2018 Financial Results |
About Transgene
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.
Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005609/en/
Contacts
Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
investorrelations@transgene.fr
or
Media:
Citigate Dewe Rogerson
David Dible / Marine Perrier, + 44 (0)20 7638 9571
transgene@citigatedr.co.uk
Source: Transgene
View this news release online at:
http://www.businesswire.com/news/home/20171221005609/en
